Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Prim Care Diabetes ; 17(1): 12-18, 2023 02.
Article in English | MEDLINE | ID: covidwho-2150390

ABSTRACT

AIM: We estimate the incidence and risk factors for fatal and non-fatal events among the COVID-19 infected subjects based on the presence of obesity or diabetes during the initial three epidemiological waves in our region. METHODS: This was a retrospective cohort study. A primary care database was used to identify persons with COVID-19. We stratified for subjects who either had diabetes mellitus or obesity. The follow-up period for study events was up to 90 days from inclusion. RESULTS: In total, 1238,710 subjects were analysed. Subjects with diabetes mellitus or obesity were older and had a worse comorbidity profile compared with groups without these conditions. Fatal events were more frequent among people with diabetes and during the first wave. In the second and third waves, the number of study events decreased. Diabetes was a risk factor for fatal events in all models, while obesity was only in the model adjusted for age, sex, diabetes and COVID-19 waves. HIV, cancer, or autoimmune diseases were risk factors for mortality among subjects with COVID-19 in the fully-adjusted model. CONCLUSIONS: Diabetes was an independent risk factor for mortality among people with COVID-19. The number of fatal events decreased during the second and third waves in our region, both in those with diabetes or obesity.


Subject(s)
COVID-19 , Diabetes Mellitus , Humans , COVID-19/diagnosis , COVID-19/epidemiology , Spain/epidemiology , Retrospective Studies , Diabetes Mellitus/diagnosis , Diabetes Mellitus/epidemiology , Obesity/diagnosis , Obesity/epidemiology , Primary Health Care
2.
Cardiovasc Diabetol ; 21(1): 216, 2022 10 19.
Article in English | MEDLINE | ID: covidwho-2079423

ABSTRACT

BACKGROUND: It is not clear whether pre-existing macrovascular complications (ischemic heart disease, stroke or peripheral artery disease) are associated with health outcomes in people with diabetes mellitus hospitalized for COVID-19. METHODS: We conducted cohort studies of adults with pre-existing diabetes hospitalized for COVID-19 infection in the UK, France, and Spain during the early phase of the pandemic (between March 2020-October 2020). Logistic regression models adjusted for demographic factors and other comorbidities were used to determine associations between previous macrovascular disease and relevant clinical outcomes: mortality, intensive care unit (ICU) admission and use of invasive mechanical ventilation (IMV) during the hospitalization. Output from individual logistic regression models for each cohort was combined in a meta-analysis. RESULTS: Complete data were available for 4,106 (60.4%) individuals. Of these, 1,652 (40.2%) had any prior macrovascular disease of whom 28.5% of patients died. Mortality was higher for people with compared to those without previous macrovascular disease (37.7% vs 22.4%). The combined crude odds ratio (OR) for previous macrovascular disease and mortality for all four cohorts was 2.12 (95% CI 1.83-2.45 with an I2 of 60%, reduced after adjustments for age, sex, type of diabetes, hypertension, microvascular disease, ethnicity, and BMI to adjusted OR 1.53 [95% CI 1.29-1.81]) for the three cohorts. Further analysis revealed that ischemic heart disease and cerebrovascular disease were the main contributors of adverse outcomes. However, proportions of people admitted to ICU (adjOR 0.48 [95% CI 0.31-0.75], I2 60%) and the use of IMV during hospitalization (adjOR 0.52 [95% CI 0.40-0.68], I2 37%) were significantly lower for people with previous macrovascular disease. CONCLUSIONS: This large multinational study of people with diabetes mellitus hospitalized for COVID-19 demonstrates that previous macrovascular disease is associated with higher mortality and lower proportions admitted to ICU and treated with IMV during hospitalization suggesting selective admission criteria. Our findings highlight the importance correctly assess the prognosis and intensive monitoring in this high-risk group of patients and emphasize the need to design specific public health programs aimed to prevent SARS-CoV-2 infection in this subgroup.


Subject(s)
COVID-19 , Diabetes Mellitus , Myocardial Ischemia , Adult , Humans , COVID-19/diagnosis , COVID-19/therapy , Respiration, Artificial , SARS-CoV-2 , Risk Factors , Hospitalization , Critical Care , Diabetes Mellitus/diagnosis , Diabetes Mellitus/epidemiology , Diabetes Mellitus/therapy
3.
Front Public Health ; 9: 758347, 2021.
Article in English | MEDLINE | ID: covidwho-1463526

ABSTRACT

Aim: The study aim was to assess the association of vitamin D supplementation before hospital admission and severe outcomes in subjects admitted for COVID-19. Methods: We performed a cross-sectional analysis of pseudonymised medical record data from subjects admitted to the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) for COVID-19 during March and April 2020. The composite primary study outcome was defined as death and/or invasive mechanical ventilation (IMV). Association between risk factors and study outcomes was evaluated by bivariate analysis, followed by logistic regression analysis. Results: In total, 1,267 persons were hospitalised during the observation period. Overall, 14.9% of the subjects were on active vitamin D supplementation treatment before admission. The subjects in the vitamin D group were significantly older than subjects without vitamin D supplementation. We observed higher rates of the primary outcome (death and/or IMV) among the persons with previous use of vitamin D (30.1 vs. 22.9% in those not receiving treatment). In the bivariate analysis, previous use of vitamin D was positively associated with death and/or IMV [odds ratio (OR): 1.45 95% CI: 1.03; 2.04]; however, after adjustment for other risk factors this association disappeared (OR: 1.09 95%CI: 0.65; 1.81). Conclusion: We did not find an association between vitamin D supplementation before hospital admission and death and/or IMV in subjects admitted for COVID-19. The age and the burden of age-associated comorbidities were independently associated with the in-hospital events.


Subject(s)
COVID-19 , Vitamin D , Cross-Sectional Studies , Dietary Supplements , Humans , Morbidity , SARS-CoV-2
4.
Med Clin (Engl Ed) ; 157(6): 288-293, 2021 Sep 24.
Article in English | MEDLINE | ID: covidwho-1401701

ABSTRACT

Tuberculosis (TB) is the leading cause of infectious mortality in the world, affecting mainly developing countries (DC), while diabetes (DM) is one of the most prevalent chronic diseases. This review analyzes the fact that diabetes is currently an important risk factor for developing TB, also presenting more complicated TB, more relapses and higher mortality. The DCs and the fourth world of the large cities are those with the highest incidence of TB and an increase in DM, which will make it difficult to control tuberculosis disease. At the same time, the COVID-19 pandemic is complicating the management of both diseases due to the difficulty of access to control and treatment and the worsening of socioeconomic inequalities. It is necessary to establish a bidirectional screening for TB and DM and promote recommendations for the joint management of both diseases.


La tuberculosis (TB) era la primera causa de mortalidad infecciosa mundial hasta la pandemia de COVID-19. Afecta sobre todo a los países en vías de desarrollo (PVD), mientras que la diabetes mellitus (DM) es una de las enfermedades crónicas más prevalentes.En esta revisión se objetiva que la DM constituye actualmente un importante factor de riesgo para desarrollar TB, presentando además TB más complicadas, más recaídas y mayor letalidad. Los PVD y el cuarto mundo de las grandes ciudades son los que presentan mayor incidencia de TB y un incremento de la DM, lo que dificultará el control de la enfermedad tuberculosa. Paralelamente, la pandemia por COVID-19 está complicando el manejo de ambas enfermedades por la dificultad de acceso al control y tratamiento y por el empeoramiento de desigualdades socioeconómicas. Es necesario establecer un cribado bidireccional de TB y DM e impulsar recomendaciones para el manejo conjunto de ambas enfermedades.

5.
BMJ Open ; 11(7): e051237, 2021 07 22.
Article in English | MEDLINE | ID: covidwho-1322827

ABSTRACT

AIM: This study's objective was to assess the risk of severe in-hospital complications of patients admitted for COVID-19 and diabetes mellitus (DM). DESIGN: This was a cross-sectional study. SETTINGS: We used pseudonymised medical record data provided by six general hospitals from the HM Hospitales group in Spain. OUTCOME MEASURES: Multiple logistic regression analyses were used to identify variables associated with mortality and the composite of mortality or invasive mechanical ventilation (IMV) in the overall population, and stratified for the presence or absence of DM. Spline analysis was conducted on the entire population to investigate the relationship between glucose levels at admission and outcomes. RESULTS: Overall, 1621 individuals without DM and 448 with DM were identified in the database. Patients with DM were on average 5.1 years older than those without. The overall in-hospital mortality was 18.6% (N=301), and was higher among patients with DM than those without (26.3% vs 11.3%; p<0.001). DM was independently associated with death, and death or IMV (OR=2.33, 95% CI: 1.7 to 3.1 and OR=2.11, 95% CI: 1.6 to 2.8, respectively; p<0.001). In subjects with DM, the only variables independently associated with both outcomes were age >65 years, male sex and pre-existing chronic kidney disease. We observed a non-linear relationship between blood glucose levels at admission and risk of in-hospital mortality and death or IMV. The highest probability for each outcome (around 50%) was at random glucose of around 550 mg/dL (30.6 mmol/L), and the risks flattened above this value. CONCLUSION: The results confirm the high burden associated with DM in patients hospitalised with COVID-19 infection, particularly among men, the elderly and those with impaired kidney function. Moreover, hyperglycaemia on admission was strongly associated with poor outcomes, suggesting that personalised optimisation could help to improve outcome during the hospital stay.


Subject(s)
COVID-19 , Diabetes Mellitus , Aged , Cross-Sectional Studies , Diabetes Mellitus/epidemiology , Humans , Male , Retrospective Studies , Risk Factors , SARS-CoV-2 , Spain/epidemiology
6.
Med Clin (Barc) ; 157(6): 288-293, 2021 Sep 24.
Article in English, Spanish | MEDLINE | ID: covidwho-1246083

ABSTRACT

Tuberculosis (TB) is the leading cause of infectious mortality in the world, affecting mainly developing countries (DC), while diabetes (DM) is one of the most prevalent chronic diseases. This review analyzes the fact that diabetes is currently an important risk factor for developing TB, also presenting more complicated TB, more relapses and higher mortality. The DCs and the fourth world of the large cities are those with the highest incidence of TB and an increase in DM, which will make it difficult to control tuberculosis disease. At the same time, the COVID-19 pandemic is complicating the management of both diseases due to the difficulty of access to control and treatment and the worsening of socioeconomic inequalities. It is necessary to establish a bidirectional screening for TB and DM and promote recommendations for the joint management of both diseases.


Subject(s)
COVID-19 , Diabetes Mellitus , Tuberculosis , Diabetes Mellitus/epidemiology , Humans , Pandemics , Risk Factors , SARS-CoV-2 , Syndemic , Tuberculosis/complications , Tuberculosis/diagnosis , Tuberculosis/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL